LICENSED ANTHRAX VACCINES AND EXPERIMENTAL PREPARATIONS AT THE STAGE OF CLINICAL TRIALS

• Main Authors: N. I. Mikshis, P. Yu. Popova, A. P. Semakova, V. V. Kutyrev
• Format: Article
• Language: Russian
• Published: Central Research Institute for Epidemiology 2017-08-01
• Series: Журнал микробиологии, эпидемиологии и иммунобиологии
• Subjects: bacillus anthracis; anthrax; anthrax vaccine; licensed vaccine; clinical trials
• Online Access: https://microbiol.elpub.ru/jour/article/view/186

High pathogenicity of anthrax agent combined with unique insensitivity of its spore forms to environmental stresses class it among extremely dangerous biological agents. Registered and effectively used anthrax vaccines made invaluable contribution to the improvement of epidemiological situation around the world. Nevertheless, neglect of non-specific prophylaxis may result in dramatic scenarios and require large-scale measures on rectification of the consequences. Efforts on the development of next-generation vaccines are aimed at safety build-up, decrease in frequency of administration, and enhancement of manufacturing technologies. The review contains the key information on licensed anthrax vaccines designed for medical use, both in the territory of the Russian Federation and abroad. Among multiple experimental developments emphasized have been preparations manufactured by various biopharmaceutical companies in compliance with GMP standards, at different phases of clinical trials in 2016.